Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326364 · ClinicalTrials.gov registry record
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 6
- Enrollment target
NCT01326364: Clinical Trial study, sponsored by Stanford University.
NCT01326364 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326364 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Interventions
- DRUG Iohexol
- DRUG Iodixanol
- PROCEDURE Stereotactic body radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
Why NCT01326364 stopped before completion
NCT01326364 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Iohexol is the first listed.
NCT01326364 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01326364 about?
NCT01326364 is a clinical study titled "Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection". The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline...
What is the current status of trial NCT01326364?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01326364?
The interventions under investigation include: Iohexol (DRUG), Iodixanol (DRUG), Stereotactic body radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT01326364?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia